Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink tough lung cancers

NCT ID NCT07698054

Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedule of oral and intravenous chemotherapy drugs. The study measures how many patients experience significant tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
toripalimab, etoposide, carboplatin, temozolomide, anlotinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer who have already tried other therapies.
What could go wrong
This is an early-phase trial with a small number of participants. The treatment may not work for everyone and could cause significant side effects from chemotherapy and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1.Age ≥18 years old, both male and female are acceptable. * 2\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards: 1. always has not received the immune therapy, 2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \> 3 months, withdrawal time \> 3 months) 3. never used anlotinib, * 3\. ECOG: 0 \~ 2; * 4 . The expected lifetime 12 weeks or more; * 5\. Major organs function normal Exclusion Criteria: * 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders; * 2.With known the special ripley sheet resistance, etoposide contraindication; * 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bayesian are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bayesian Metronomic chemotherapy SCLC, extensive stage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.